Navigation Links
InspireMD To Participate In Benchmark Investor Conference On May 30th
Date:5/24/2013

BOSTON and TEL AVIV, Israel, May 24, 2013 /PRNewswire/ --

InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, announced that Alan Milinazzo , the Company's President and Chief Executive Officer, and Craig Shore , the Company's Chief Financial Officer, will participate in the Benchmark Company, LLC One-on-One Investor Conference on Thursday May 30, 2013 at The Pfister Hotel, 424 East Wisconsin Ave., Milwaukee, WI.

The format of the conference includes a number of 1-on-1 meetings arranged by Benchmark, with investors. Investors interested in meeting with Mr. Milinazzo and Mr. Shore should contact a Benchmark representative to arrange a meeting.

The Company will discuss the global commercial plan for its MGuard[TM] Embolic Protection Stent (EPS) platform, its U.S. FDA clinical trial program, and the six month follow-up results of its MASTER I trial, which were presented yesterday at EuroPCR 2013, held May 21-24 at the Palais des Congrès in Paris, France.

About The Benchmark Company, LLC

Headquartered in New York City, The Benchmark Company, LLC is an institutional brokerage firm with offices in 12 cities throughout the United States.

About Stenting and MGuard™ EPS

Standard stents were not engineered for heart attack patients. They were designed for treating stable angina patients whose occlusion is different from that of an occlusion in a heart attack patient.

In acute heart attack patients, the plaque or thrombus is unstable and often breaks up as the stent is implanted causing downstream blockages (some of which can be fatal) in a significant portion of heart attack patients.

The MGuard EPS is integrated with a precisely engineered micro net mesh that prevents the unstable arterial plaque and thrombus (clots) that caused the heart attack blockage from breaking off.

While offering superior performance relative to standard stents in STEMI patients with regard to ST segment resolution, the MGuard EPS requires no change in current physician practice - an important factor in promoting acceptance and general use in time-critical emergency settings.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MGuard technology to make its products the industry standard for embolic protection stents and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

MGuard EPS is CE Mark approved. It is not approved for sale in the U.S. by the U.S. Food and Drug Administration (FDA) at this time.

Forward-looking Statements:

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Transition Report on Form 10-K/T and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

For additional information:
InspireMD Desk
Redington Inc.,
+1-212-926-1733
+1-203-222-7399
inspiremd@redingtoninc.com


'/>"/>
SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. InspireMD Hires Vice President of Corporate Development
2. Michael Berman Joins InspireMD Board
3. InspireMD Postpones $40 Million Registered
4. InspireMD Reports 2012 Fiscal Year Results
5. InspireMD to Present at JMP Securities Healthcare Conference on July 12th in New York
6. InspireMD to Present at JMP Securities Healthcare Conferenceon July 12th in New York
7. InspireMD Appoints Dr. James Barry to Its Board of Directors
8. InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
9. ViroPharma To Participate In Two May Healthcare Investor Conferences
10. P&P Optica Invited to Cambridge Innovation Centre for the Canadian Technology Accelerator Program, One of Eight Canadian Life Science Companies Chosen to Participate
11. AVANIR Pharmaceuticals To participate in two conferences in March
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... Food and Drug Administration (FDA) has accepted the ... for DSUVIA™ (formerly ARX-04) (sufentanil sublingual tablet, 30 ... acute pain in a medically supervised setting. The ...
(Date:2/27/2017)... FRANCISCO , Feb. 27, 2017 Fluxion ... Spain has been appointed as a ... System. The IsoFlux system will be used in Genetracer ... relevant to lung and colon cancer, with plans to ... The laboratory is utilizing Fluxion,s IsoFlux System to isolate, ...
(Date:2/26/2017)... ... February 26, 2017 , ... Rob Lowe is a well recognized television personality, ... "Informed," focuses on issues that are important to the American public and important to ... has been a hot topic around the world for a few years. , The ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Delpor, Inc. ... $224K grant from the National Institute of Mental Health (NIMH) for the further advancement ... Delpor’s PROZOR technology and is expected to deliver therapeutic levels of olanzapine ...
Breaking Biology Technology:
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
(Date:2/7/2017)... LONG BEACH, New York , February 7, 2017 ... formerly known as ID Global Solutions Corporation [OTC: IDGS], ... identification, identity management and electronic transaction processing services, is ... a reorganization of the Company. Effective January ... Chairman of the Board of Directors, CEO and President. ...
Breaking Biology News(10 mins):